Hepatitis B, Chronic
Pipeline by Development Stage
Drug Modality Breakdown
Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.
Key Trends
- HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
- Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
- High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity
Career Verdict
Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) | Gilead Sciences | $3.2B | 27% | Peak | Stable | 10.4yr |
| 2 | EPCLUSA (velpatasvir and sofosbuvir) | Gilead Sciences | $877M | 7% | Peak | Stable | 8.0yr |
| 3 | TIVICAY (dolutegravir sodium) | GSK | $657M | 6% | Peak | Declining | 3.9yr |
| 4 | TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) | GSK | $632M | 5% | Peak | Declining | 3.9yr |
| 5 | GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) | Gilead Sciences | $626M | 5% | Peak | Stable | 6.8yr |
Drug Class Breakdown
backbone of HIV treatment, stable demand
hepatitis C treatment, mature market
boosting agents in combination regimens
niche mechanism, limited growth
Career Outlook
StableInfectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.
Breaking In
Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.
For Experienced Professionals
Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.
In-Demand Skills
Best For
Hiring Landscape
Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.
Top Hiring Companies
By Department
Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.
On Market (3)
Approved therapies currently available
Competitive Landscape
35 companies ranked by most advanced pipeline stage
+5 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 11,198 patients across 50 trials
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
EFFORT Further Extension Study
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients
Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients
Emtricitabine for Naive Chinese Chronic Hepatitis B Patients
Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy
EFFORT Extension Study
EFFicacy Optimization Research of Telbivudine Therapy
Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B
A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)
Use of TDF in Patients With Inactive Chronic Hepatitis B Infection
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Related Jobs in Infectious Diseases
Associate Scientist II, Analytical Development, Raw Materials (Contract)
Data System Analyst
Clinical Data Scientist/ Methodologist
Associate Research Scientist - Vaccines
Automation Specialist I - Vaccines - First Shift
Occupational Health Nurse
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.